Success Metrics

Clinical Success Rate

20.0%

Based on 1 completed trials

Completion Rate

20%(1/5)

Active Trials

0(0%)

Results Posted

100%(1 trials)

Terminated

4(80%)

Phase Distribution

Ph phase_1

60%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(4)

Detailed Status

Terminated4

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

20.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

terminated480%

completed120%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_2

A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)

NCT04439071

terminatedphase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT04439071Phase 2

A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)

Terminated

NCT03761069Phase 1

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Terminated

NCT00704821Phase 1

PTC299 for Treatment of Advanced Cancer

Terminated

NCT00911248Phase 2

PTC299 for Treatment of Neurofibromatosis Type 2

Terminated

NCT00508586Phase 1

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5